Hosted by the School of Medicine at Cardiff University
Register on Eventbrite
Over the last two decades Green's lab has focused on the mechanisms whereby blood stem cells are subverted to cause haematological malignancies, using human MPNs as a tractable model. In work which transformed MPN diagnosis and catalysed development of therapeutic JAK inhibitors, we and others identified phenotypic driver mutations in JAK2 and CALR which activate the JAK/STAT pathway and are present in most MPN patients. We have subsequently employed a variety of approaches to describe the biological consequences of these mutations at molecular, cellular and organismal levels. In addition to altering clinical practice, our studies have led to unexpected insights into cancer biology as well as normal cytokine signalling, including novel roles for STAT proteins in controlling blood stem cell behaviour.
Bio: Tony Green is currently Professor of Haemato-oncology at the University of Cambridge and Honorary Consultant Haematologist at Cambridge University Hospitals NHS Trust. He was Head of the University of Cambridge Department of Haematology (2000-2020), President of the European Hematology Association (2015-1017) and Director of the Wellcome-MRC Cambridge Stem Cell Institute (2016-2022).
His early research explored the transcriptional control of normal blood stem cells and more recently the mechanisms by which stem cells are subverted to cause haematological malignancies, using the myeloproliferative neoplasms (MPNs) as a tractable model. In work which spans basic, translational and clinical research he has identified key causal mutations, described their biological consequences, led practice-changing clinical studies and discovered basic mechanisms of broad relevance for both cancer biology and cytokine signalling.